IPSEN (OTCMKTS:IPSEY) Sees Large Volume Increase – Still a Buy?

IPSEN (OTCMKTS:IPSEY) shares saw unusually-high trading volume on Friday . Approximately 10,866 shares changed hands during mid-day trading, an increase of 396% from the previous session’s volume of 2,191 shares.The stock last traded at $48.86 and had previously closed at $50.7044.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on IPSEY shares. UBS Group cut shares of IPSEN from a “strong-buy” rating to a “hold” rating in a research report on Thursday, January 8th. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of IPSEN in a research report on Tuesday, April 14th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, IPSEN has an average rating of “Hold”.

IPSEN Price Performance

The company has a 50-day simple moving average of $47.02 and a 200-day simple moving average of $40.97.

About IPSEN

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).